These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33489083)

  • 21. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimavanserin use in a movement disorders clinic: a single-center experience.
    Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N
    Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
    Hermanowicz S; Hermanowicz N
    Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
    Pahwa R; Isaacson SH; Small GW; Torres-Yaghi Y; Pagan F; Sabbagh M
    Neurol Ther; 2022 Dec; 11(4):1571-1582. PubMed ID: 35906500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
    Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
    Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 31. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
    Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
    Isaacson SH; Coate B; Norton J; Stankovic S
    J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.
    Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL
    Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
    Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G
    World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
    Kitten AK; Hallowell SA; Saklad SR; Evoy KE
    Innov Clin Neurosci; 2018 Feb; 15(1-2):16-22. PubMed ID: 29497575
    [No Abstract]   [Full Text] [Related]  

  • 39. Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review.
    Colijn MA
    J Neuropsychiatry Clin Neurosci; 2024 Jul; ():0. PubMed ID: 39034670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.
    Alva G; Cubała WJ; Berrio A; Coate B; Abler V; Pathak S
    J Alzheimers Dis; 2024; 98(1):265-274. PubMed ID: 38427485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.